Communiqué de presse : Cenrifki (tolebrutinib) de Sanofi approuvé dans l’UE comme premier médicament ciblant la progression du handicap dans la sclérose en plaques secondairement progressive sans rechutes

The European Commission has approved Sanofi's Cenrifki (tolebrutinib), a brain-penetrating Bruton tyrosine kinase inhibitor, for treating secondary progressive multiple sclerosis (SPMS) without relapses. The approval is based on the Phase 3 HERCULES trial, which demonstrated that Cenrifki significantly delayed disability progression. The drug will be commercially available in Germany this year, with careful risk management protocols due to identified hepatic safety concerns.